Posaconazole pharmacokinetics in elderly healthy volunteers and elderly patients

A. Sansone, R. Courtney, G. KrishnaL. Pedicone (Kenilworth, USA)

Author address: 



Objectives: The pharmacokinetics (PK) of many medications may be altered in the elderly population. Because alterations in PK can potentially affect clinical outcomes, the PK parameters ofPosaconazole (POS), an extended-spectrum investigational triazole antifungal agent, were examined in healthy elderly persons ("¡65 years), and the clinical implications of age-related PK differences were evaluated. Methods: We conducted a meta-analysis of POS steady-state PK data from 5 clinical studies in healthy volunteers. PK data from elderly healthy volunteers were compared with those of elderly patients with invasive fungal infections (IFIs) who participated in an open-label trial that evaluated POS efficacy and safety. Study participants received POS oral suspension 800 mg/day in divided doses. Because POS plasma concentrations at steady state are relatively constant, AUC values in healthy subjects could be directly compared with the average steadystate plasma concentration in patients. Results: Out of a total of 174 healthy volunteers in the metaanalysis, 24 (14%) were "¡ 65 years. POS exposure was approximately 24% higher in elderly than that in adult (1864 years) subjects. Mean AUC values for adult (n = 150) and elderly subjects were 28.495 and 35.444 ngí†h/mL, respectively. These observations were consistent with PK data from elderly patients with IFIs. The IFI study included 330 patients; 33 (10%) were elderly, ofwhom25 were included in thePKanalysis. The average concentration values were 1056 ng/mLand 817 ng/mLin elderly patients and patients 18 to 64 years, respectively. Although POS exposure wasapproximately29% higher in elderly than that in the adult patients

abstract No: 


Full conference title: 

    • ECCMID 15th (2005)